Clinical trials in Swidnica – page 13

985 clinical trials in Swidnica, Poland across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in PolandBadaniaKliniczne.pl

Swidnica at a glance

985

clinical trials

Research sites1

Quick filters

985 trials in Swidnica

Open in trial search

Interstitial lung disease+1

Recruiting

Assessing Hemodynamic Effect and Safety of TX000045 in Adults with Pulmonary Hypertension Secondary to Interstitial Lung Disease

InvestigationalNo placebo

Assessing Hemodynamic Effect and Safety of TX000045 in Adults with Pulmonary Hypertension Secondary to Interstitial Lung Disease

InvestigationalNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:TX000045
Sponsor:Tectonic Operating Company Inc.

Contact Research Centre

Plasma cell myeloma

Recruiting

Cevostamab, Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 1‑3 Lines of Therapy

Registered drugNo placebo

Cevostamab, Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 1‑3 Lines of Therapy

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Carfilzomib
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

Pharmacokinetics and safety of subcutaneous vs intravenous human normal immunoglobulin in adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

Registered drugNo placebo

Pharmacokinetics and safety of subcutaneous vs intravenous human normal immunoglobulin in adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Human Normal Immunoglobulin
Sponsor:Grifols Therapeutics LLC

Contact Research Centre

Chronic obstructive pulmonary disease

Recruiting

Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Investigational

Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Lunsekimig
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Plasma cell myeloma refractory

Recruiting

Phase 3 Study Comparing JNJ-79635322 with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma after 1‑3 Prior Treatments

InvestigationalNo placebo

Phase 3 Study Comparing JNJ-79635322 with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma after 1‑3 Prior Treatments

InvestigationalNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:JNJ-79635322
Sponsor:Janssen Cilag International

Contact Research Centre

Systemic lupus erythematosus+3

Recruiting

A Phase 3 Study of Enpatoran to Treat Active Cutaneous Lupus in Patients With or Without Systemic Disease

Investigational

A Phase 3 Study of Enpatoran to Treat Active Cutaneous Lupus in Patients With or Without Systemic Disease

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Enpatoran hemihydrate
Sponsor:Merck Healthcare KGaA

Contact Research Centre

Pancreatic carcinoma metastatic

Recruiting

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Incyte Corp.

Contact Research Centre

Bladder cancer

Recruiting

Study of Enfortumab Vedotin and Pembrolizumab for Bladder Preservation in Patients with Muscle‑Invasive Bladder Cancer

Registered drugNo placebo

Study of Enfortumab Vedotin and Pembrolizumab for Bladder Preservation in Patients with Muscle‑Invasive Bladder Cancer

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Enfortumab Vedotin
Sponsor:Astellas Pharma Global Development Inc.

Contact Research Centre

Colitis ulcerative

Recruiting

A Phase 2a Study Evaluating the Efficacy and Safety of MK-8690 in Adults with Moderately to Severely Active Ulcerative Colitis

Investigational

A Phase 2a Study Evaluating the Efficacy and Safety of MK-8690 in Adults with Moderately to Severely Active Ulcerative Colitis

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:MK-8690
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Hereditary angioedema

Recruiting

Long‑Term Safety Study of ADX‑324 in Participants with Hereditary Angioedema (Phase 3 Extension)

Investigational

Long‑Term Safety Study of ADX‑324 in Participants with Hereditary Angioedema (Phase 3 Extension)

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:ADX-324
Sponsor:Adarx Pharmaceuticals Inc.

Contact Research Centre

Mantle cell lymphoma

Recruiting

Phase 3 Study of Orelabrutinib with Rituximab and Bendamustine vs. Rituximab and Bendamustine in Treatment‑Naïve Mantle Cell Lymphoma Patients

Registered drug

Phase 3 Study of Orelabrutinib with Rituximab and Bendamustine vs. Rituximab and Bendamustine in Treatment‑Naïve Mantle Cell Lymphoma Patients

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Orelabrutinib
Sponsor:Innocare Pharma Inc.

Contact Research Centre

Hodgkin's disease

Recruiting

Study of nivolumab plus drug combination versus standard first-line therapy in patients with advanced Hodgkin lymphoma

Registered drugNo placebo

Study of nivolumab plus drug combination versus standard first-line therapy in patients with advanced Hodgkin lymphoma

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Brentuximab Vedotin
Sponsor:Polska Grupa Badawcza Chloniakow

Contact Research Centre

Other cities in Poland

The busiest research cities in the country

All 236 cities in Poland

Clinical research in Swidnica

What the registry says about research in the country

01 Inflammatory Conditions

Innovative research focusing on inflammatory disorders, including trials evaluating new treatments for psoriatic arthritis and rheumatoid arthritis. Studies aim to assess novel therapeutic approaches using biologics and targeted medications.

Psoriatic Arthritis Studies
Rheumatoid Arthritis Treatment
Inflammatory Disease Management

Advanced therapies being tested to improve patient outcomes and quality of life.

02 Gastrointestinal Research

Comprehensive studies investigating treatments for inflammatory bowel diseases, including trials for Crohn's Disease and ulcerative colitis. Research focuses on novel therapeutic agents and long-term disease management.

Crohn's Disease Therapies
Ulcerative Colitis Treatments
Long-term Disease Management

Multiple trials exploring innovative approaches to treating gastrointestinal conditions.

03 Metabolic and Pain Management

Studies addressing obesity, knee osteoarthritis, and chronic pain conditions. Research includes evaluation of new medications for weight management and innovative approaches to pain relief.

Weight Management Therapies
Osteoarthritis Treatment
Pain Management Solutions

Cutting-edge research combining multiple therapeutic approaches for complex conditions.

04 Specialty Conditions

Focused research on unique conditions including thyroid eye disease, chronic spontaneous urticaria, and rotator cuff tendinopathy. Studies aim to develop targeted treatments for these specific medical needs.

Endocrine Disorders
Autoimmune Conditions
Musculoskeletal Treatments

Specialized therapeutic approaches for distinct medical conditions.

Back to Poland All countries